John B. Henneman III
John B. Henneman III's purchase track record
John B. Henneman III has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/7/2026 | OFIX | $61K | -12.2% | pending | — |
| 5/1/2026 | ANIK | $73K | +29.8% | pending | — |
| 3/13/2024 | APRE | $50K | -22.2% | -42.0% | +7.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aprea Therapeutics Announces October Conference Presentations. Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.
Transaction History
| ANIK | ▲ Buy | Grant | 10,402 | $0 | 6/18/2026 | View on chart |
| APRE | ▲ Buy | Grant | 3,135 | $0 | 6/16/2026 | View on chart |
| OFIX | ▲ Buy | Grant | 14,965 | $0 | 6/10/2026 | View on chart |
| OFIX | ▲ Buy | Open Market | 5,000 | $61K | 5/7/2026 | View on chart |
| ANIK | ▲ Buy | Open Market | 5,000 | $73K | 5/1/2026 | View on chart |
| ANIK | ▲ Buy | Grant | 14,164 | $0 | 6/20/2025 | View on chart |
| OFIX | ▲ Buy | Grant | 18,841 | $0 | 6/18/2025 | View on chart |
| APRE | ▲ Buy | Grant | 1,045 | $0 | 6/5/2025 | View on chart |
| ANIK | ▲ Buy | Grant | 5,771 | $0 | 7/9/2024 | View on chart |
| APRE | ▲ Buy | Grant | 1,045 | $0 | 6/20/2024 | View on chart |
| OFIX | ▲ Buy | Grant | 15,152 | $195K | 6/18/2024 | View on chart |
| APRE | ▲ Buy | Open Market | 6,860 | $50K | 3/13/2024 | View on chart |
| APRE | ▲ Buy | Grant | 500 | $0 | 8/23/2023 | View on chart |
| ANIK | ▲ Buy | Grant | 6,500 | $0 | 6/14/2023 | View on chart |
| OFIX | ▲ Buy | Grant | 14,052 | $0 | 1/5/2023 | View on chart |
| APRE | ▲ Buy | Grant | 5,995 | $0 | 7/28/2022 | View on chart |
| ANIK | ▲ Buy | Grant | 7,954 | $0 | 6/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ANIK Stock Moves Amid Broader Biotech Sector News
Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.
ANIK Stock Moves Amid Broader Biotech Sector News. Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.